. .
.. ,
1
.. , ..., ., 1,
.. , ...2
1
ǻ, .
2
5 .
,
().
( , )
.
,
.
,
,
.
, ,
.
,
,
. : , ,
, , -,
.
,
,
,
.
40-60% [7].
36,9% [17].
,
, 22,7 %
[21, 35].
( 4 5 %).
10
[27, 28].
-
[2,
10, 33].
.
(pirosis),
,
,
, ,
.
( ) .
. . (1997)
,
, ,
[1].
, :
,
.
()
VII (2007)
: -
() ,
,
,
,
,
,
-
,
[5].
().
,
[16].
, ,
( []
12 )
13,3 %,
23,6% ( ) [6].
,
,
,
[26].
,
().
20 30% [34].
,
, 5-4-
(revexepride).
70-78% [4, 8, 24]. ,
(
:
)
,
,
: 30,59%
21,42% , < 0,001.
60
:
(40,95 %
37,52% . = 0,021),
(29,41 % 19,22 %
, = 0,00001)
(16,99% 13,61%, = 0,0015)
[11].
, , 30-60
.
[24].
,
( 92
%), [19].
,
.
.
,
,
( ),
( ),
(,
);
(
, .).
,
,
(
).
,
. (Candida
albicans), ( ,
, ), (
, Mycobacterium tuberculosis)
.
. pylori ,
[25].
.
,
.
, , ,
,
,
( ).
,
,
( , ).
;
, ,
( -),
,
, ,
.
,
,
,
,
(
).
,
()
:
:
(
[,
]);
,
;
;
() ,
, ;
,
, ,
; (
,
) [22].
( - 3,
2006; -
1),
,
- [3,8].
,
,
(
).
,
().
(3-5 ) (,
.)
[13].
-.
,
( )
.
.
.
20-22- ,
. 30-
1/3
, 38-
.
(
, )
.
[14].
[29].
,
,
[30].
, ,
.
,
,
, , , ,
(,
, -); ,
,
(, , , , ,
, ). ,
.
,
,
,
. ,
,
.
. ,
,
( ) ()
, ( )
.
-:
4,0.
, ,
4,0,
,
,,
. ,
( 4,0) [27].
,
.
. 5 %
4,0
,
[32].
,
,
,
. , ,
:
, ,
+- (),
()
[14, 15].
.
,
, -1, ,
[12].
-
,
.
-.
.
(, ),
.
.
,
,
- .
[36].
.
Cheng F. . .,
176
.
(, 2012)
35,5 %
.
,
[20].
, .
.
, .
.
:
97%, 88%.
,
,
( ,
),
(
, ),
, .
,
-
[9, 10].
.
:
;
;
;
, ,
, , ,
, (,
); ;
15
;
;
(, ,
-,
()
, ),
-;
:
; , ;
( ).
2013
,
[28].
V
(),
.
.
(-,
)
, 1-2
30-60 .
( 6-8 )
( ) .
: 80% 26
90-98 % .
-,
12 .
(). ,
,
.
2-.
II III
( )
.
.
(,
, ,
)
2-
() 10
.
,
() .
.
.
,
80
. ,
,
,
(, )
(,
) 250
(
).
,
,
[23].
[18].
,
- ().
[31].
:
,
, [14].
.
- ;
- ,
,
;
,
.
,
, ,
.
- ., . .
2- . . 1997.
- .., ..,
.., .., ..
. ,
-
. ., 2006. 19 .
- ..
/ /
.
, , 2007.
- .., .., ..
.
. , 2010. 480
.
- .., ..,
.. . :
// . 2009. 7,
5-9.
- .., ..,
.. .
(). .
2011. 1. . 45-50.
- .., .., ..
XXI . // .2004.
4. . 10-14.
-
.., .. .
. . 2007,
2, . 45-49.
- .., .. .
. , 2005.
- .. .
, ,
.,2010.
- .., .., ..
-
//
. 2010. 12. . 17-23.
- .., ..,
.. -
- .
. 2013,
XVIII, 2. 36-46.
- ..
.
.
. 2008. 2. .
89-93.
- ..
?
. Consilium Medicus.
2003. . 5. N6.
- .., ..
//
.
2000. 4. . 150.
- . .
, 5, 2004, . 122-126.
- .., ..
- .
pylori-
// . .
., ., . 2002.
5 ( 17). . 41.
- Abbasinazari M., Panahi Y., Mortazavi
S.A. Fahimi P., Valizadegan G., Mohtashami
R., Pourhoseingholi M.A., Shirvani Bakhtiari
K. Effect of a Combination of Omeprazo/e
Plus Sustained Release Baclofen Versus
Omeprazole Alone on Symptoms of Patients
with Gastroesophageal Reflux Disease (GERDJ.
Iran. J. Pharm. Res. 2014 Fall; 13(4}:
1221-6.
- Carisson R., Dent J., Bolling-Sternevald
E. The usefulness of a structured
questionnaire in the assessment of
symptomatic gastroesophageal reflux disease.
Scand. J. Gastroenterol. 1998:33: 1023-9.
- Cheng P.K., Albert D.M., Maydonovitch
.L, Wong R.K., Moawad F.J. Categorization
of Patients With Reflux Symptoms Referred
for pH and Impedance Testing While Off
Therapy.
- Chiriia I., Petrariu P., Drug V., et al.
Epidemiology of gastroesophageal reflux and
relationship with diet in adult urban
population. J. Gasfroenterol. Hepafol. 2013;
28 (suppl. 3): 503.
- Cooke R.A., Anggiansah A., Chambers W.J.
et al. A prospective study of esophageal
function in patients with normal coronary
angiograms and controls with angina. II Gut.
1998. Vol. 42. P. 323-329.
- de Bortoli N.. Martinucci I., Savarino
E., Tutuian R., Frazzoni M., Piaggi P.,
Berfani L, Furnari M., Franchi R., Russo S.,
Bellini M., Savarino V., Santino M.
Association Between Baseline Impedance
Values and Response Proton Pump Inhibitorsin
Patients With Heartburn. Clin. Gasfroenterol.
Hepafol. 2014 Dec. 11. pii:
SI542-3565(14)01764-9.
- Dent J., Vakil N., Jones R., et al.
Validation of the reflux disease
questionnaire for the diagnosis of
gastroesophageal reflux disease in primary
care. Gut. 2007; 56 suppl. 111: 328.
- Iwanczak ., Laszewicz W., Iwanczak P.,
Dzierzanowska-Fangrai K., Rozynek M.,
Dzierzanowska D., Gosciniak G., Dlugosz J.
Task force of the Polish Society of
Gastroenterology: genotypic and clinical
differences of seropositive Helicobacfer
pylori children and adults in the Polish
population. J. Physiol. Pharmacol. 2014 Dec;
65 (6); 801-7.
- Jha LK., Maradey-Romero C, Gadam R,
Hershcovici ., Pass O. I., Quan S. P.,
Guillen J., Pass R. The effect of antireflux
treatment on the frequency of awakenings
from sleep in patients with Gastroesophageal
reflux disease. Neurogasfroenferol Motil.
2015 Feb; 27 (2): 237-45.
- Joelsson ., Johnsson F. Heartburn the
acid test. Guf 1989:30:1523-5.
- Katz P.O., Gerson L.., Vela M.F.
Guidelines for the Diagnosis and Management
of Gastroesophageal Reflux Disease. II The
American Journal of Gastroenterology.
2013.Vol. 108.P. 308-328.
- Kessing B.F., Bredenoord A.J., Saleh
., Smout A.J. Effects of Anxiety and
Depression in Patients With Gastroesophageal
Reflux Disease. Clin Gasfroenterol Hepafol.
2014 Dec. 9. pii; S1542-3565(14)01742-X. doi:
10.1016/j.cgh.2014.11.034.
- Kasap E., Ayer A., Bozoglan H., Ozen C.,
Eslek I., Yuceyar H. Schizophrenia and
gastroesophageal reflux symptoms. Indian J.
Psychiatry. 2015 Jan-Mar; 57 II): 73-7.
- Kondo ., Oshima Tl, Tomita ., Fukui
H., Okada H., Watari J., Miwa H. The
Non-sferoidal Anti-inflammatory Drug
Diclofenac Reduces Acid-Induced Heartburn
Symptoms in Healthy Volunteers. Clin
Gasfroenterol Hepafol. 2015 Jan 26. pii:
S1542-3565(15)00100-7. doi:
10.1016/j.cgh.2015.01.014.
- Martinez S.D, Malagon I.B., Garewal
H.S., et al. Non-erosive reflux disease,
acid reflux and symptom pattern. Aliment.
Pharmacol. Ther. 2003; 17: 537-45. Richter
I. E. The patient with refractory
gastroesophageal reflux disease. Dis.
Esophagus 2006; 19:443-47.
- Tack J., Zerbib F., Blondeau K., des
Varannes S. ., Piessevaux H., Borovicka J.,
Mion F., Fox M., Bredenoord A. J., Louis H.,
Dedrie S., Hoppenbrouwers M., Meulemans A.,
Rykx A., Thielemans L., Ruth M. Randomized
clinical trial: effect of the 5-HT4 receptor
agonist revexepride on reflux parameters in
patients with persistent reflux symptoms
despite PPI treatment. Neurogasfroenferol
Motil. 2015 Feb; 27 (2): 258-68.
- Vakil N. Disease definition, clinical
manifestations, epidemiology and natural
history of GERD. Best Pracf. Res. Clin.
Gasfroenterol. 2010; 24: 759-76.
- Wang K, Duan L, Xia Z, Xu Z, Ge Y.
Esophageal motility characteristics of
refractory heartburn: a study based on high
resolution manometry and 24 hour
pH-impedance monitoring. Ihonghua Yi Xue la
Zhi. 2014 Sep 16:94 (34): 2650-5.
http://www.gastroscan.ru
| |
|  |
|
Спутники
РН
SpaceX
Роскосмос
NASA